Aflibercept and Bromfenac

The combination of aflibercept and bromfenac is a therapeutic approach used primarily for treating exudative (wet) age-related macular degeneration (AMD). This combination therapy involves intravitreal injections of aflibercept along with topical application of bromfenac. ## Mechanism and Efficacy Aflibercept is an anti-VEGF (vascular endothelial growth factor) agent that works by binding to VEGF-A and placental growth factor (PlGF), preventing them from activating VEGF receptors[1]. Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) that is applied topically as eye drops[1]. Clinical studies have demonstrated that this combination therapy is more effective than aflibercept monotherapy in treating wet AMD[1][2]. A pilot study conducted on 27 patients showed improved visual acuity outcomes in the combination therapy group compared to patients receiving only aflibercept[1]. ## Clinical Benefits The primary advantages of this combination therapy include: 1. **Reduced injection frequency**: Patients receiving the combination therapy required significantly fewer intravitreal aflibercept injections over a 2-year period (7.4 ± 1.0 injections) compared to those receiving aflibercept alone (9.0 ± 1.9 injections)[3][5]. 2. **Comparable anatomical outcomes**: Despite fewer injections, the combination therapy achieved similar improvements in central retinal thickness (CRT) compared to aflibercept monotherapy[3][5]. 3. **Maintained visual acuity**: Both treatment approaches showed improvements in best-corrected visual acuity (BCVA) after 2 years compared to baseline values[3][5]. ## Treatment Protocol The typical treatment protocol involves: - Monthly intravitreal injections of aflibercept - Daily topical application of bromfenac 0.09% eye drops - Additional injections administered up to 3 months after the third administration, depending on treatment response[1] ## Safety Profile No significant complications, including endophthalmitis or corneoscleral diseases, were reported in clinical studies of this combination therapy[3]. This suggests that the addition of topical bromfenac to intravitreal aflibercept treatment is generally well-tolerated. ## Clinical Applications This combination therapy may be particularly beneficial for patients with exudative AMD who: - Have difficulty with frequent hospital visits - Would benefit from reduced injection frequency - Have not previously undergone vitrectomy surgery or anti-VEGF injections[4] The combination of aflibercept and bromfenac represents a promising alternative to anti-VEGF monotherapy for the management of exudative AMD, potentially reducing treatment burden while maintaining therapeutic efficacy.